X4 Pharmaceuticals (XFOR) Research & Development (2017 - 2026)

X4 Pharmaceuticals (XFOR) has reported Research & Development for 10 consecutive years, with $15.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development fell 17.83% year-over-year to $15.1 million; the trailing twelve-month figure through Jun 2026 stood at $66.4 million (down 14.6% YoY), and the FY2025 full-year result was $72.7 million, down 10.93% from the prior year.
• Research & Development fell to $15.1 million in Q2 2026 per XFOR's latest filing, from $15.4 million in the prior quarter.
• Across five years, Research & Development topped out at $22.1 million in Q1 2023 and bottomed at $13.8 million in Q2 2022.
• Historically, Research & Development has averaged $17.7 million across 5 years, with a median of $18.4 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Research & Development jumped 56.34% in 2022, then fell 19.68% in 2023.
• Over 5 years, Research & Development stood at $19.0 million in 2022, then dropped by 19.68% to $15.3 million in 2023, then soared by 42.1% to $21.7 million in 2024, then decreased by 14.66% to $18.5 million in 2025, then fell by 18.58% to $15.1 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $15.1 million, $15.4 million, and $18.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.